Cargando…

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment

Osteoarthritis (OA) is a leading cause of physical disability among aging populations, with no available drugs able to efficiently restore the balance between cartilage matrix synthesis and degradation. Also, OA has not been accurately classified into subpopulations, hindering the development toward...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Heng, Wu, Yan, Pan, Zongyou, Yu, Dongsheng, Chen, Pengfei, Zhang, Xiaoan, Wu, Haoyu, Zhang, Xiaolei, An, Chengrui, Chen, Yishan, Qin, Tian, Lei, Xiaoyue, Yuan, Chunhui, Zhang, Shufang, Zou, Weiguo, Ouyang, Hongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020860/ https://www.ncbi.nlm.nih.gov/pubmed/29898872 http://dx.doi.org/10.1016/j.ebiom.2018.06.002

Ejemplares similares

High-Resolution Dissection of Chemical Reprogramming from Mouse Embryonic Fibroblasts into Fibrocartilaginous Cells
por: Chen, Yishan, et al.
Publicado: (2020)

Classification of four distinct osteoarthritis subtypes with a knee joint tissue transcriptome atlas
por: Yuan, Chunhui, et al.
Publicado: (2020)

Hype or hope of hyaluronic acid for osteoarthritis: Integrated clinical evidence synthesis with multi-organ transcriptomics
por: Zhao, Kun, et al.
Publicado: (2022)

Computational flow cytometric analysis to detect epidermal subpopulations in human skin
por: Zhang, Lidan, et al.
Publicado: (2021)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

A Gelatin-sulfonated Silk Composite Scaffold based on 3D Printing Technology Enhances Skin Regeneration by Stimulating Epidermal Growth and Dermal Neovascularization
por: Xiong, Si, et al.
Publicado: (2017)

Msx1(+) stem cells recruited by bioactive tissue engineering graft for bone regeneration
por: Zhang, Xianzhu, et al.
Publicado: (2022)

Osteoarthritis subpopulations and implications for clinical trial design
por: Bierma-Zeinstra, Sita MA, et al.
Publicado: (2011)

SFRP4(+) stromal cell subpopulation with IGF1 signaling in human endometrial regeneration
por: Wu, Bingbing, et al.
Publicado: (2022)

TFEB, a potential therapeutic target for osteoarthritis via autophagy regulation
por: Zheng, Gang, et al.
Publicado: (2018)

Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma
por: Han, Xiao, et al.
Publicado: (2017)

Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
por: Xu, Chong‐Rui, et al.
Publicado: (2016)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
por: Patel, Nishant, et al.
Publicado: (2017)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer
por: Huafeng, Jia, et al.
Publicado: (2018)

STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-κB signaling pathway
por: Guo, Qiang, et al.
Publicado: (2021)

BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway
por: Jin, Huang, et al.
Publicado: (2019)

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
por: Naruo, Yoshimi, et al.
Publicado: (2011)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

A high-resolution route map reveals distinct stages of chondrocyte dedifferentiation for cartilage regeneration
por: Chen, Yishan, et al.
Publicado: (2022)

Correction: A high-resolution route map reveals distinct stages of chondrocyte dedifferentiation for cartilage regeneration
por: Chen, Yishan, et al.
Publicado: (2022)

Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy
por: Song, Xinyu, et al.
Publicado: (2018)

Discovery of Muscle-Tendon Progenitor Subpopulation in Human Myotendinous Junction at Single-Cell Resolution
por: Yan, Ruojin, et al.
Publicado: (2022)

Limonin Inhibits IL-1β-Induced Inflammation and Catabolism in Chondrocytes and Ameliorates Osteoarthritis by Activating Nrf2
por: Jin, Jie, et al.
Publicado: (2021)

Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib
por: Copps, Beatrice, et al.
Publicado: (2020)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
por: Ni, Xiao Ling, et al.
Publicado: (2017)

Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Hong, Dongsheng, et al.
Publicado: (2016)

Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
por: Xu, Fei, et al.
Publicado: (2012)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with (125)I-EGF
por: Björkelund, Hanna, et al.
Publicado: (2011)

Inhibition of Rac1 activity by controlled release of NSC23766 from chitosan microspheres effectively ameliorates osteoarthritis development in vivo
por: Zhu, Shouan, et al.
Publicado: (2015)

Current research on pharmacologic and regenerative therapies for osteoarthritis
por: Zhang, Wei, et al.
Publicado: (2016)

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
por: Li, Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6jijd0del5fvgiuhmq541uesco